enter
airway
epitheli
cell
influenza
parainfluenzaand
coronavirus
reli
host
cell
proteas
activ
viral
protein
involv
membran
fusion
one
proteas
transmembran
proteas
serin
recent
proven
crucial
hemagglutinin
cleavag
human
influenza
virus
sinc
catalyt
site
divers
serin
proteas
link
influenza
parainfluenzaand
coronaviru
activ
structur
similar
activ
site
inhibitor
airway
proteas
could
broad
therapeut
applic
multipl
respiratori
virus
altern
superior
select
could
achiev
alloster
inhibitor
anoth
critic
proteas
though
still
infanc
airway
proteas
inhibit
repres
attract
hostcel
target
approach
combat
respiratori
virus
influenza
global
scale
season
influenza
b
virus
caus
around
million
case
sever
ill
year
result
death
exist
drug
direct
influenza
neuraminidas
oseltamivir
zanamivir
peramivir
laninamivir
proton
channel
amantadin
rimantadin
show
rather
modest
clinic
efficaci
establish
potenti
resist
besid
pandem
variant
may
time
emerg
due
gene
reassort
human
zoonot
influenza
virus
rapid
viru
spread
global
societi
novel
medic
invent
mode
action
urgent
need
treat
prevent
sever
influenza
infect
vulner
popul
recent
brave
research
need
battl
respiratori
virus
report
call
host
cell
target
antivir
approach
sinc
anticip
exhibit
higher
barrier
drug
resist
focu
new
paradigm
combat
influenza
respiratori
viru
infect
direct
toward
airway
proteas
essenti
role
viru
activ
complementari
concis
analysi
detail
review
recent
publish
elsewher
influenza
viru
hemagglutinin
ha
mediat
two
event
viru
entri
ha
globular
head
bind
sialyl
cell
surfac
glycan
result
viru
endocytosi
ii
ha
stem
refold
endosom
ph
liber
fusion
peptid
caus
fusion
viral
endosom
membran
releas
viral
genom
host
cell
cytoplasm
henc
ha
target
entri
blocker
may
interact
ha
receptor
bind
site
inhibit
viru
attach
ii
bind
ha
stem
region
inhibit
fusion
instanc
prevent
refold
acid
ph
design
broad
influenza
ha
blocker
anyth
easi
given
high
sequenc
variabl
among
ha
subtyp
antigen
drift
ha
differ
receptor
usag
avian
versu
human
influenza
virus
multival
natur
hareceptor
interact
instanc
small
molecul
influenza
fusion
inhibitor
appear
inadequ
sinc
gener
show
subtyp
specif
rapid
emerg
resist
altern
indirect
strategi
prevent
proteolyt
activ
ha
inhibit
host
cell
proteas
respons
thereof
influenza
virusinfect
cell
ha
synthes
precursor
protein
kda
assembl
noncoval
link
homotrim
obtain
fusion
capac
need
cleav
cellular
proteas
kda
kda
enabl
insert
fusion
peptid
locat
nterminu
neg
charg
caviti
prime
ha
low
phdepend
fusion
superfamili
differ
fold
yet
catalyt
triad
asphiss
trypsinlik
enzym
hpaiv
possess
kkrxr
motif
significantli
suppress
cleavag
effici
furin
pc
activ
type
ii
transmembran
serin
proteas
ttsp
specif
mosaic
serin
proteas
largeform
mspl
splice
variant
contrast
protein
human
influenza
b
virus
possess
cleavag
loop
monobas
ie
singl
arginin
cleavag
site
featur
also
present
pandem
influenza
virus
whether
includ
virus
subtyp
inhibit
hacleav
host
cell
proteas
induc
product
noninfecti
virion
thu
halt
viru
replic
type
inhibitor
could
two
major
strength
resist
less
like
develop
sinc
host
protein
target
instead
highli
mutabl
viral
protein
ii
broad
activ
divers
respiratori
virus
may
envisag
sinc
besid
influenza
viru
sever
respiratori
virus
reli
activ
similar
proteas
see
henc
drug
might
also
use
tackl
outbreak
respiratori
virus
specif
antivir
drug
avail
summar
tabl
divers
trypsinlik
proteas
tlp
abl
activ
human
influenza
virus
vitro
vivo
viru
propag
chicken
egg
cleavag
perform
blood
clot
factor
xa
allanto
fluid
madin
darbi
canin
kidney
mdck
cell
cultur
addit
trypsin
need
multicycl
replic
ha
activ
airway
infect
person
sever
tlp
candid
enzym
identifi
pictur
still
far
complet
role
well
establish
transmembran
proteas
serin
member
ttsp
famili
integr
membran
protein
extracellular
ctermin
serin
proteas
domain
ntermin
cytoplasm
domain
ko
mice
found
surviv
infect
influenza
viru
lethal
wildtyp
wt
mice
furthermor
genom
wide
associ
studi
show
patient
higher
express
level
higher
risk
sever
infect
pandem
viru
increas
suscept
influenza
circul
human
influenza
subtyp
proteas
profil
less
well
defin
appear
straindepend
compar
wt
mice
prove
equal
slightli
less
vulner
lethal
infect
third
strain
avirul
mice
becam
lethal
ten
passag
mice
sinc
passag
viru
carri
nglycosyl
mutat
bottom
ha
stalk
region
loss
glycan
may
alter
access
cleavag
loop
provid
access
altern
host
proteas
second
tlp
candid
close
relat
enzym
infect
influenza
strain
doubleko
mice
display
lower
morbid
mortal
though
show
bodi
weight
loss
patholog
process
ha
thu
besid
addit
proteas
abl
cleav
activ
ha
virus
possibl
explan
provid
conform
differ
seen
avail
crystal
structur
cleavag
loop
extend
protein
surfac
wherea
cleavag
site
less
expos
henc
may
access
divers
proteolyt
enzym
might
allow
effici
replic
viru
possibl
explain
symptom
infect
tend
sever
compar
subtyp
role
human
airway
trypsinlik
proteas
hat
propos
sever
year
ago
still
await
vivo
verif
exist
viabl
hatko
mous
model
systemat
analysi
cleavag
pattern
influenza
ha
subtyp
perform
cell
assay
use
coexpress
plu
hat
proteas
test
condit
cleavag
seem
overal
effici
hat
although
mark
subtyp
depend
seen
neither
two
proteas
abl
activ
ha
subtyp
analysi
cleavag
site
sequenc
point
amino
acid
absolut
determin
recognit
hat
besid
hat
member
ttsp
famili
name
matriptas
differenti
express
squamou
cell
carcinoma
gene
mspl
mosaic
serin
proteas
largeform
splice
variant
mediat
cell
membraneassoci
cleavag
certain
ha
subtyp
investig
perform
cell
expos
recombin
proteas
engin
overexpress
proteas
studi
effect
matriptas
demonstr
cell
cell
line
deriv
human
bronchial
epithelia
matriptas
gene
knockdown
result
signific
impair
influenza
replic
vivo
investig
hinder
fact
matriptaseko
mice
nonviabl
addit
secret
proteas
like
plasmin
kallikrein
klk
type
perform
cleavag
although
proteas
tabl
experiment
data
role
airway
proteas
activ
influenza
coronaand
paramyxovirus
abl
activ
influenza
viru
cell
cultur
evid
yet
confirm
role
airway
influenzainfect
individu
case
influenza
b
viru
activ
mechan
larg
unexplor
cell
cultur
overexpress
hat
result
cleavag
multicycl
replic
influenza
b
viru
disagre
howev
vivo
find
influenza
b
viru
display
effici
cleavag
full
pathogen
mice
unlik
influenza
influenza
b
viru
absolut
requir
exogen
trypsin
replic
certain
mdck
cell
line
indic
cell
express
yet
unidentifi
proteas
act
ha
influenza
b
far
less
effici
influenza
serin
proteas
mention
classifi
trypsinlik
proteas
tlp
sinc
cleav
peptid
bond
posit
charg
amino
acid
arginin
lysin
specif
link
presenc
neg
charg
asp
residu
bottom
specif
pocket
figur
today
crystal
structur
avail
matriptas
sever
kallikrein
hat
crystallograph
inform
indic
high
degre
structur
homolog
activ
site
region
tlp
contain
catalyt
triad
chymotrypsin
number
outsid
catalyt
domain
sever
exosit
exist
higher
structur
divers
critic
role
substrat
bind
recognit
consequ
activ
site
target
inhibitor
higher
chanc
possess
broader
activ
spectrum
wherea
exosit
alloster
bind
prefer
develop
highli
select
tlp
inhibitor
proofofconcept
pre
clinic
evid
alreadi
avail
sinc
broad
serin
proteas
inhibitor
aprotinin
camostat
suppress
influenza
viru
replic
cell
cultur
mous
model
inhibit
serin
proteas
involv
cleavag
inflamm
moreov
aerosol
aprotinin
approv
therapi
russia
shown
shorten
symptom
durat
human
infect
influenza
parainfluenza
viru
howev
aprotinin
protein
unfavor
pharmacokinet
wherea
camostat
coval
binder
nonspecif
proteas
inhibitor
potenti
sideeffect
achiev
agent
superior
potenc
safeti
specif
inhibitor
relev
airway
proteas
inhibitor
influenza
laport
naesen
airway
proteas
particularli
need
design
classic
type
proteas
inhibitor
peptidomimet
substrat
analogu
tlp
inhibitor
high
bind
affin
obtain
coupl
mimick
moieti
peptidyl
portion
optim
size
composit
enabl
tight
fit
activ
site
among
two
seri
inhibitor
contain
either
sulfonyl
sever
analogu
display
k
valu
nm
enzymat
assay
antivir
strategi
protein
produc
escherichia
coli
best
inhibitor
tabl
k
valu
nm
interestingli
produc
clear
inhibit
cleavag
viru
replic
cell
endogen
express
proteas
like
inhibitor
tabl
contain
prolin
darginin
also
nice
activ
k
valu
nm
recombin
hat
enzym
indic
inhibitor
dual
activ
two
relev
airway
proteas
achiev
unfortun
compound
also
produc
strong
inhibit
relat
tlp
thrombin
plasmin
factor
xa
suggest
prolin
substitut
entail
reduc
select
besid
select
issu
safeti
serin
proteas
inhibitor
larg
depend
whether
bind
revers
classic
inhibitor
show
coval
bind
catalyt
serin
case
pseudo
irrevers
exampl
camostat
irrevers
proteas
inhibitor
may
pose
safeti
issu
howev
matriptas
inhibitor
tabl
possess
ketobenzothiazol
moieti
form
coval
yet
revers
bond
catalyt
serin
compound
caus
signific
reduct
influenza
replic
cell
whether
sole
attribut
inhibit
matriptas
unclear
sinc
effect
relev
proteas
like
report
entir
differ
approach
aim
develop
exosit
binder
alloster
inhibitor
discoveri
inhibitor
requir
highthroughput
screen
ht
fragmentbas
approach
unlik
peptidomimet
activ
site
binder
ration
design
known
peptid
substrat
biochem
ht
recombin
protein
yield
five
hit
compound
includ
bromhexin
use
mucolyt
drug
hit
tabl
display
select
ie
poor
activ
matriptas
trypsin
thrombin
combin
nonpeptidomimet
structur
suggest
could
exosit
alloster
inhibitor
bromhexin
shown
suppress
prostat
cancer
metastasi
mous
model
line
role
overexpress
promot
prostat
cancer
metastasi
influenza
evalu
five
compound
virusinfect
cell
observ
inhibitori
effect
laport
unpublish
data
indic
hittolead
optim
still
requir
anoth
factor
take
account
compound
abil
permeat
cell
membran
exampl
unclear
whether
influenza
suppress
polypeptid
kda
compound
aprotinin
occur
extracellularli
rather
compound
intern
influenza
cleavag
occur
transgolgi
network
transport
newli
synthes
along
secretori
pathway
apic
cell
membran
virion
releas
infect
cell
subsequ
entri
new
host
cell
mainli
local
transgolgi
network
cleav
newli
synthes
hand
sinc
hat
mainli
resid
cell
membran
proteas
domain
direct
toward
extracellular
space
proteas
cleav
releas
incom
viru
despit
grow
interest
host
cell
factor
target
antivir
intervent
possibl
toxic
logic
concern
seem
verifi
hat
airway
proteas
sinc
hat
singl
doubl
knockout
mice
perfectli
healthi
matriptas
howev
indispens
ubiquit
express
known
role
develop
epidermi
hair
follicl
cellular
immun
system
one
uniqu
benefit
block
relat
airway
proteas
besid
influenza
viru
sever
respiratori
virus
could
target
shown
activ
fusion
protein
paramyxovirus
ie
metapneumoviru
trypsindepend
parainfluenza
subtyp
sendai
viru
likewis
human
coronavirus
includ
deadli
sar
mer
variant
cleavag
activ
viral
spike
protein
cell
surfac
enabl
cathepsinindepend
host
cell
entri
sprotein
mer
sar
coronavirus
also
cleav
coexpress
mspl
protein
also
vivo
evid
sinc
camostat
prove
effect
protect
mice
lethal
infect
sar
coronaviru
sinc
antivir
medic
paramyxovirus
coronavirus
current
lack
broaderact
airway
proteas
inhibitor
could
well
suit
fill
gap
final
airway
proteas
inhibitor
could
combin
convent
antivir
drug
obtain
synergist
effect
reduc
risk
resist
instanc
combin
oseltamivir
serin
proteas
inhibitor
bapa
found
suppress
influenza
viru
replic
human
airway
epitheli
cell
remark
lower
concentr
treatment
inhibitor
alon
trypsinlik
proteas
human
airway
repres
uniqu
target
suppress
infect
influenza
respiratori
virus
reli
enzym
replic
signific
support
recent
proof
mous
clinic
studi
proteas
essenti
replic
influenza
virus
proteas
inhibitor
may
act
two
differ
mechan
strong
yet
prefer
revers
bind
activ
site
interfer
exosit
alloster
domain
advantag
activ
site
binder
would
potenti
suppress
also
relev
airway
proteas
includ
hat
design
select
inhibitor
would
facilit
better
insight
protein
structur
proteas
research
also
need
precis
defin
proteas
cleavag
profil
human
particularli
influenza
b
virus
whether
use
monoor
combin
therapi
airway
proteas
inhibitor
could
repres
uniqu
class
host
celltarget
drug
broad
spectrum
antivir
activ
